FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
The Food and Drug Administration (FDA) has granted an expanded approval for Exablate Neuro, which utilizes MRI-guided ultrasound treatment, in staged bilateral pallidothalamic tractotomy procedures for patients with advanced Parkinson’s disease.
Insightec, the manufacturer of Exablate Neuro, said the expanded approval provides targeted ultrasound treatment of the pallidothalamic tract and a viable alternative for patients with Parkinson’s disease-related dyskinesia, bradykinesia and rigidity.
“This new indication represents a significant step forward in how integrated movement disorder teams will approach the treatment of Parkinson's disease," noted Michael Kaplitt, M.D., who is affiliated with the Department of Neurological Surgery at Weill Cornell Medicine-New York Presbyterian Hospital. "As the lead investigator of the clinical trial evaluating the safety and effectiveness of the staged bilateral procedure with the Exablate system, I'm encouraged by the results and am excited about what it offers my patients."
Results from the aforementioned multicenter multinational clinical trial assessing Exablate Neuro in staged bilateral pallidothalamic tractotomy procedures for Parkinson’s disease will be published later in 2025, according to Insightec.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
July 31st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 31st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 31st 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 31st 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
